InvestorsHub Logo
Followers 166
Posts 3144
Boards Moderated 0
Alias Born 11/03/2014

Re: nsgmd5 post# 346990

Wednesday, 01/13/2021 12:54:47 AM

Wednesday, January 13, 2021 12:54:47 AM

Post# of 718776
Also, nsgmd5, if you can read between the lines, and you know where to look, you will see the obvious connections between: UCLA, NWBio, Merck, DCVax & Keytruda. Take a look at the ATL-DC + Keytruda trial Sponsors & Collaborators on the clinical trials.org site link below:

UCLA - Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Merck Sharp & Dohme Corp.
Phase One Foundation
Oncovir, Inc

https://clinicaltrials.gov/ct2/show/NCT04201873

Then take a look at who is the Phase One Foundation, and the money ($400,000) they gave to UCLA to conduct this study:

https://www.phaseonefoundation.org/latest-news/cancer-researchers-develop-immunebased-therapies-for-deadly-brain-tumors

Then, go to the above link and look for this paragragraph:

The funding will help open a clinical trial testing a combination treatment strategy using checkpoint inhibitors in conjunction with a personalized dendritic cell vaccine, which was developed by Liau at UCLA



Then, touch the blue link in this paragraph, it says: “was developed by Liau”. This blue link will take you to this page:

https://newsroom.ucla.edu/releases/personalized-vaccine-increase-long-term-survival-glioblastoma

This page clearly shows you that the ATL-DC vaccine developed by Dr. Linda Liau is DCVax-L. It says the following:

The vaccine, known as DCVax-L, uses a person’s own white blood cells to help activate the immune system to fight cancer





Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News